Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.

ABSTRACT: Bryostatin 1, in clinical trials or preclinical development for cancer, Alzheimer's disease, and a first-of-its-kind strategy for HIV/AIDS eradication, is neither readily available nor optimally suited for clinical use. In preceding work, we disclosed a new class of simplified bryostatin analogs designed for ease of access and tunable activity. Here we describe a final step diversification strategy that provides, in only 25 synthetic steps, simplified and tunable analogs with bryostatin-like PKC modulatory activities.

SUBMITTER: Wender PA 

PROVIDER: S-EPMC4334251 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature